Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

1H NMR based urinary metabolites profiling dataset of canine mammary tumors

ABSTRACT:

The identification of efficient and sensitive biomarkers for non-invasive tests is one of the major challenges in cancer diagnosis. To address this challenge, metabolomics is widely applied for identifying biomarkers that detects abnormal changes in cancer patients. Canine mammary tumors exhibit physiological characteristics identical to those in human breast cancer and serve as a useful animal model to conduct breast cancer research. Here, we aimed to provide a reliable large-scale metabolite dataset collected from dogs with mammary tumors, using proton nuclear magnetic resonance spectroscopy. We identified 55 metabolites in urine samples from 20 benign, 87 malignant, and 49 healthy control subjects. This dataset provides details of mammary tumor-specific metabolites in dogs and insights into cancer-specific metabolic alterations that share similar molecular characteristics.

INSTRUMENT(S): Nuclear Magnetic Resonance (NMR) -

SUBMITTER: Hojung Nam

PROVIDER: MTBLS2550 | MetaboLights | 2022-02-24

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MTBLS2550	Other
	FILES	Other
	a_MTBLS2550_NMR_CrAdj_metabolite_profiling.txt	Txt
	a_MTBLS2550_NMR_metabolite_profiling.txt	Txt
	files-all.json	Other

Items per page:

1 - 5 of 9

Similar Datasets

iTRAQ in proteomic analysis of potential biomarkers in invasive cancer, ductal carcinoma in situ, and mammary fibroadenoma

Project description:Breast malignancy is a serious threat to women’s health around the world. However, for invasive, ductal carcinomas, and mammary fibroadenoma, there is an urgent demand for better breast malignancy-linked biomarkers. The current study was designed to identify diagnostic and/or therapeutic protein biomarkers for breast tumors. iTRAQ proteomic analysis was employed to characterize differentially expressed protein biomarkers. We identified several potential protein biomarkers that can be recommended for further testing as diagnostic and/or therapeutic targets in breast tumors.

2020-10-13 | PXD019963 | Pride

Global gene expression profiling of primary tumors and lung metastases using a mouse model of spontaneous metastatic mammary carcinoma

Project description:In this study, we explored the molecular basis of site-specific metastasis of breast cancer to the lungs in a clinically relevant model based on the JygMC(A) cell line. In this dataset, we include expression data from JygMC(A) primary mammary tumors, lung metastases, normal mammary glands and normal lung parenchyma.

2015-11-02 | GSE63627 | GEO

Targeted mRNA gene expression profiling of primary tumors and lung metastases using a mouse model of spontaneous metastatic mammary carcinoma

Project description:In this study, we explored the molecular basis of site-specific metastasis of breast cancer to the lungs in a clinically relevant model based on the JygMC(A) cell line. In this dataset, we include expression data from JygMC(A) primary mammary tumors (carcinoma and EMT-like areas), lung metastases, normal mammary glands and normal lung parenchyma.

2015-11-02 | GSE63951 | GEO

RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass and molecular pathway cancer diagnostics

Project description:We report RNA-sequencing data of 283 blood platelet samples, including 228 tumor-educated platelet (TEP) samples collected from patients with six different malignant tumors (non-small cell lung cancer, colorectal cancer, pancreatic cancer, glioblastoma, breast cancer and hepatobiliary carcinomas). In addition, we report RNA-sequencing data of blood platelets isolated from 55 healthy individuals. This dataset highlights the ability of TEP RNA-based 'liquid biopsies' in patients with several types with cancer, including the ability for pan-cancer, multiclass cancer and companion diagnostics.

2015-10-30 | GSE68086 | GEO

Stem cell gene expression profiling of primary mammary tumors derived from orthotopic xenograft tumors treated with Sulforaphane (SFN) or control II

Project description:In this study, we explored stem cell markers profile of mammary tumor initiation and growth derived from a human breast cancer cell line (MDA-MB-231 D3H1 Luci). In this dataset, we include expression data from primary mammary tumors pre-treated with Sulforaphane for 2 weeks (daily i.p. injection of 50mg SFN/kg) and kept treatment after cell injection for more 3 weeks and Saline 0.9% as a Control.

2019-01-03 | GSE80764 | GEO

Stem cell gene expression profiling of primary mammary tumors derived from orthotopic xenograft tumors treated with Sulforaphane (SFN) or control I

2019-01-03 | GSE80763 | GEO

The protein profile of mammary gland and tumors between Brca1-WT and MT miece by DIA-MS(DIA-data)

Project description:WT mammary gland(WTMG),mutant-MG(MTMG),WT breast tumors(WTBT),MTBT and MTBT-adjacent MG were collected to do data-independent acquisiton(DIA)mass to find the intrinsic factors that is associated with Brca1-deficiency induced breast cancer.

2022-02-20 | PXD030328 | Pride

The protein profile of mammary gland and tumors between Brca1-WT and MT miece by DIA-MS(DDA data)

2022-02-20 | PXD030355 | Pride

Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits

Project description:Breast tumors expressing lower levels of Estrogen Receptor (ER) represent a distinct subset of breast cancer characterized by the emergence of basal-like characteristics within tumors that are traditionally considered luminal-like. Lineage tracing of these low-ER tumors in the MMTV-PyMT mouse mammary tumor model revealed that the basal-like tumor cells within these tumors arose from normal luminal epithelial cells, suggesting that luminal-to-basal plasticity is responsible for the evolution and emergence of basal-like characteristics within these tumors. This study aims to identify the potential drivers of this plasticity by using single-cell RNA sequencing to identify populations of lineage-restricted luminal cells and luminal-derived basal cells within the tumor, and comparing their gene expression profiles.

2023-03-01 | GSE214815 | GEO

Consequences of sEH deletion in the polyoma middle T (PyMT) breast cancer tumor proteome

Project description:The aim of this investigation was to study the consequences of interfering with soluble epoxide hydrolase (sEH) expression on tumor growth and metastasis in genetically modified animals that spontaneously generate tumors without the exogenous application of high concentrations of epoxide mediators or inhibitors. Therefore, breast cancer development was studied in mice expressing the polyoma middle T oncogene (PyMT) under the control of the mouse mammary tumor virus promoter, to induce spontaneous mammary tumors. To facilitate the study of endogenous sEH activity in tumor growth, PyMT mice were then crossed with sEH-/- mice to generate sEH-deficient mice that spontaneously generate breast tumors (so called PyMTsEH mice). For these analyses, primary tumors were removed from 20 week old mice.

2021-09-14 | PXD026214 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data